Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women’s cancers
Cody J. Peer(National Institutes of Health), William D. Figg(National Cancer Institute), Christina M. Annunziata(National Cancer Institute), Jeffers Nguyen(Johns Hopkins University), Lori M. Minasian(National Cancer Institute), Jung Min Lee(Kyung Hee University), Elise C. Kohn(National Cancer Institute), Jeffrey A. Roth(National Cancer Institute), Louis Rodgers(National Cancer Institute)
Cited by 10
Related Papers
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JAMA Oncology|2015|1k
Precisely printable and biocompatible silk fibroin bioink for digital light processing 3D printing
|Nature Communications|2018|964